Nemus Bioscience is developing novel cannabinoid-based therapeutics for global medical challenges. It has an exclusive relationship with the University of Mississippi to develop cannabinoid compounds and targets. Its lead product NB1111 is a prodrug of THC being developed for glaucoma, a large global market with high unmet need. Preclinical studies show NB1111 significantly reduces eye pressure and may protect optic nerve cells, outperforming THC. Nemus aims to become a leading developer of second and third generation cannabinoid medicines.
AMBS is a regenerative medicine company developing new treatments for CNS disorders and regenerative medicine. It has several programs and subsidiaries developing treatments for conditions like Parkinson's disease, burns, cancer, and retinal diseases. Its lead programs include Eltoprazine for Parkinson's disease levodopa-induced dyskinesia through its subsidiary Elto Pharma, and recombinant MANF protein for retinal conditions like retinitis pigmentosa through its subsidiary MANF Therapeutics. AMBS is currently trading at very low prices but has achieved much higher values in the past, and it believes further progress in its clinical programs could increase its valuation.
- IntelGenx Corp is a drug delivery company focused on oral film technologies. They have a pipeline of products using their VersaFilm and AdVersa drug delivery platforms.
- They have a state-of-the-art manufacturing facility in Montreal approved by Health Canada. Their pipeline includes products for migraine, erectile dysfunction, schizophrenia, and neurodegenerative diseases.
- They are conducting clinical trials for a Montelukast VersaFilm to treat cognitive impairment associated with neurodegenerative diseases like Alzheimer's, with promising preclinical and Phase I results shown.
Intelgenx presentation november 2017 final2ItelGenx
IntelGenx is a drug delivery company that develops oral thin film products and mucoadhesive tablets. They have a pipeline of products addressing significant market opportunities in migraine, erectile dysfunction, schizophrenia, neurodegenerative diseases, and other areas. Their technology platforms include VersaFilm oral thin films and AdVersa mucoadhesive tablets. They have a business model of partnering with other companies to develop and commercialize products using a full service approach. They have a state-of-the-art manufacturing facility and are advancing a robust pipeline of product candidates.
Vivos Inc. presented a new brachytherapy tool called RadioGel for treating cancers in humans and animals. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle. It is designed to deliver a high radiation dose directly to tumors while minimizing damage to healthy tissue. The company expects to generate near-term revenue from veterinary applications and international licensing as it pursues FDA approval for multiple human cancer indications starting with skin cancer. Vivos has strong leadership and advisors in place and an intellectual property protected platform technology to become an important new tool for cancer treatment.
Globavir is presenting its corporate strategy to target tropical diseases through accelerated drug development. The presentation highlights GBV006, a late-stage drug candidate for the treatment of dengue fever derived from two FDA-approved drugs. GBV006 has shown potent antiviral activity and 100% survival in animal studies. Globavir also has a pipeline of diagnostic tests and is pursuing partnerships to develop and commercialize its products globally.
IntelGenx is an innovative pharmaceutical film company presenting its product pipeline and technology platforms to investors. The presentation discusses IntelGenx's oral thin film and buccal film technologies, product development strategies, business model, pipeline of products including treatments for migraines, erectile dysfunction, and brain degenerative diseases, and clinical trial results. It highlights a de-risked product candidate using montelukast to treat brain degenerative diseases and significant market opportunities for its pipeline products.
BioVie Inc. (OTCQB: BIVI) is a clinical-stage company developing innovative drug therapies for liver disease. The Company’s drug candidate, BIV201 (continuous infusion terlipressin), has an Orphan Drug designation for the treatment of refractory ascites, FDA Fast Track status, and US patent pending. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The FDA has never approved terlipressin. BioVie is targeting this landmark achievement.
Visit BIVIinfo.com to learn more.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for liver disease. The Company’s drug candidate, BIV201 (continuous infusion terlipressin), has an Orphan Drug designation for the treatment of refractory ascites, FDA Fast Track status, and US patent pending. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The FDA has never approved terlipressin. BioVie is targeting this landmark achievement.
AMBS is a regenerative medicine company developing new treatments for CNS disorders and regenerative medicine. It has several programs and subsidiaries developing treatments for conditions like Parkinson's disease, burns, cancer, and retinal diseases. Its lead programs include Eltoprazine for Parkinson's disease levodopa-induced dyskinesia through its subsidiary Elto Pharma, and recombinant MANF protein for retinal conditions like retinitis pigmentosa through its subsidiary MANF Therapeutics. AMBS is currently trading at very low prices but has achieved much higher values in the past, and it believes further progress in its clinical programs could increase its valuation.
- IntelGenx Corp is a drug delivery company focused on oral film technologies. They have a pipeline of products using their VersaFilm and AdVersa drug delivery platforms.
- They have a state-of-the-art manufacturing facility in Montreal approved by Health Canada. Their pipeline includes products for migraine, erectile dysfunction, schizophrenia, and neurodegenerative diseases.
- They are conducting clinical trials for a Montelukast VersaFilm to treat cognitive impairment associated with neurodegenerative diseases like Alzheimer's, with promising preclinical and Phase I results shown.
Intelgenx presentation november 2017 final2ItelGenx
IntelGenx is a drug delivery company that develops oral thin film products and mucoadhesive tablets. They have a pipeline of products addressing significant market opportunities in migraine, erectile dysfunction, schizophrenia, neurodegenerative diseases, and other areas. Their technology platforms include VersaFilm oral thin films and AdVersa mucoadhesive tablets. They have a business model of partnering with other companies to develop and commercialize products using a full service approach. They have a state-of-the-art manufacturing facility and are advancing a robust pipeline of product candidates.
Vivos Inc. presented a new brachytherapy tool called RadioGel for treating cancers in humans and animals. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle. It is designed to deliver a high radiation dose directly to tumors while minimizing damage to healthy tissue. The company expects to generate near-term revenue from veterinary applications and international licensing as it pursues FDA approval for multiple human cancer indications starting with skin cancer. Vivos has strong leadership and advisors in place and an intellectual property protected platform technology to become an important new tool for cancer treatment.
Globavir is presenting its corporate strategy to target tropical diseases through accelerated drug development. The presentation highlights GBV006, a late-stage drug candidate for the treatment of dengue fever derived from two FDA-approved drugs. GBV006 has shown potent antiviral activity and 100% survival in animal studies. Globavir also has a pipeline of diagnostic tests and is pursuing partnerships to develop and commercialize its products globally.
IntelGenx is an innovative pharmaceutical film company presenting its product pipeline and technology platforms to investors. The presentation discusses IntelGenx's oral thin film and buccal film technologies, product development strategies, business model, pipeline of products including treatments for migraines, erectile dysfunction, and brain degenerative diseases, and clinical trial results. It highlights a de-risked product candidate using montelukast to treat brain degenerative diseases and significant market opportunities for its pipeline products.
BioVie Inc. (OTCQB: BIVI) is a clinical-stage company developing innovative drug therapies for liver disease. The Company’s drug candidate, BIV201 (continuous infusion terlipressin), has an Orphan Drug designation for the treatment of refractory ascites, FDA Fast Track status, and US patent pending. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The FDA has never approved terlipressin. BioVie is targeting this landmark achievement.
Visit BIVIinfo.com to learn more.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for liver disease. The Company’s drug candidate, BIV201 (continuous infusion terlipressin), has an Orphan Drug designation for the treatment of refractory ascites, FDA Fast Track status, and US patent pending. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The FDA has never approved terlipressin. BioVie is targeting this landmark achievement.
The document is an investor presentation by IntelGenx, an innovative drug delivery solutions company. It summarizes the company's business strategy, product pipeline, and financial performance. Key points include IntelGenx's focus on repurposing drugs using its oral thin film technology, its partnerships with companies like RedHill and Chemo, its pipeline of products including treatments for migraines and erectile dysfunction, and the construction of its new manufacturing facility. The presentation highlights IntelGenx's potential for growth in the oral thin films market.
NE3107 is a small molecule in Phase 3 clinical trials for Alzheimer's disease and Parkinson's disease. It works by inhibiting neuroinflammation and insulin resistance, two key drivers of cognitive decline. A Phase 3 trial for Alzheimer's is underway testing NE3107's ability to slow cognitive decline compared to placebo. Preclinical studies show NE3107 reduces inflammation, enhances insulin sensitivity, and has neuroprotective effects, supporting its potential in neurodegenerative diseases. A Phase 2 trial will assess NE3107's activity and safety when combined with L-dopa for Parkinson's disease.
One in 8 U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. Following breast cancer surgery in the adjuvant setting, a HER2/neu 3+ patient typically receives Herceptin® in the first year, with the hope that their breast cancer will not recur, and with the odds of recurrence slowly decreasing over the first 5 years after surgery. Herceptin® has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting. In the neoadjuvant setting, a patient receives treatment before surgery and based on the results of a biopsy at surgery, will receive the same or more potent treatment after surgery. Kadcyla® has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting. Accordingly, we believe that GP2 may be used to address the 50% of recurring patients who do not respond to either Herceptin® or Kadcyla®.
- The document is an investor presentation for IntelGenx Corp from April 2018.
- It provides an overview of IntelGenx, including its business strategies, product pipeline, clinical trial results, manufacturing facilities, and leadership team.
- The presentation highlights IntelGenx's drug delivery technology platforms, focus on developing generic and repurposed products, and partnerships with pharmaceutical companies.
One in 8 U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. Following breast cancer surgery in the adjuvant setting, a HER2/neu 3+ patient typically receives Herceptin® in the first year, with the hope that their breast cancer will not recur, and with the odds of recurrence slowly decreasing over the first 5 years after surgery. Herceptin® has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting. In the neoadjuvant setting, a patient receives treatment before surgery and based on the results of a biopsy at surgery, will receive the same or more potent treatment after surgery. Kadcyla® has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting. Accordingly, we believe that GP2 may be used to address the 50% of recurring patients who do not respond to either Herceptin® or Kadcyla®.
SciSparc is a specialty pharmaceutical company developing unique cannabinoid technologies for treatment of central nervous system disorders. The proprietary compounds capitalize on the biochemistry of receptors that specialize in modulating the central nervous system (CNS) to create therapeutics that mitigate the adverse symptoms associated with CNS disorders.
Aptorum Group Limited (NASDAQ: APM) is a pharmaceutical company dedicated to
developing and commercializing novel therapeutics to tackle unmet medical needs.
Aptorum's current drug pipeline includes indications in orphan diseases, infectious
diseases, and metabolic diseases. In 2021, the company plans to bring two candidates to
clinical trials. Aptorum’s Smart-ACT™ platform is designed to bring an average of three
drug candidates for orphan diseases to clinical trials every 12-18 months. The company is
now preparing to launch a dietary supplement for women undergoing menopause and
experiencing related symptoms, including osteoporosis. Targeting a global woman’s health
supplement market that is expected to reach $17 billion in 2025, Aptorum is expected to
generate near-term revenue with significant long-term growth potential.
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of drug candidates intended to transform existing treatment and prevention paradigms. Its lead Phase 3 antifungal candidate, rezafungin, will report Phase 3 data at the end of 2021. The potential peak sales opportunity for rezafungin in the US is ~$750M. In addition, the Company is developing Drug-Fc Conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform.
Virios Therapeutics is a clinical-stage biotechnology company focused on advancing novel, dual mechanism antiviral therapies to treat conditions associated with virally triggered or maintained immune responses, such as Fibromyalgia (“FM”). Immune responses related to the activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) have been postulated as a potential root cause triggering and/or sustaining chronic illnesses such as FM, irritable bowel disease (“IBS”), and chronic fatigue syndrome, all of which can be characterized by waxing and waning symptom flare-ups with no obvious etiology. Virios’ lead development candidate (“IMC-1”) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress HSV-1 replication, with the end goal of reducing virally promoted disease symptoms.
HR Compliance & Insurance Benefit Perspectives: What Employers Should Be Awar...Rea & Associates
Guidelines for employees are constantly changing but it’s important that businesses stay on top of mandates and regulations. What risks should organizations be informed about? Is your organization able to have varied insurance premiums for vaccinated vs. non-vaccinated employees?
Join Rea & Associates and Huntington Insurance for a deep dive into best practices for exposures, insurance perspectives, and vaccine mandates and regulations.
This document provides an overview of NEMUS Bioscience, a publicly traded life sciences company focused on developing cannabinoid-based therapies. Some key points:
- NEMUS has exclusive partnerships with the University of Mississippi, the only entity licensed to study cannabinoids, giving it access to 48 years of research.
- It has a pipeline of drug candidates targeting large markets like glaucoma, chemotherapy side effects, and pain, in preclinical and research stages.
- Target indications include ocular diseases, anti-infectives for bacteria/viruses, and pain syndromes.
- Recent milestones include in-licensing a CBD derivative from UM to research chemotherapy induced
Nemus Bioscience is developing cannabinoid-based therapies focused on treating glaucoma and other conditions. Their lead product NB1111 is a THC prodrug being developed for glaucoma, with plans to initiate a Phase 1b/2a clinical trial in Australia. If successful, NB1111 has the potential to provide IOP reduction and neuroprotection - advantages over current glaucoma drugs. Nemus has partnerships with Emerald Health Sciences and the University of Mississippi providing intellectual property rights and development expertise in cannabinoid research.
This document provides an overview of NEMUS Bioscience, a biotech company focused on developing cannabinoid-based therapies. It discusses NEMUS' partnership with the University of Mississippi, its product pipeline including treatments for glaucoma, chemotherapy side effects, and antibiotic-resistant infections, and provides highlights of recent milestones such as positive studies of a drug for glaucoma and the identification of a molecule for chemotherapy-induced neuropathy. The document also gives financial information about NEMUS and states that it is advancing therapies in large potential markets through proprietary cannabinoid molecules.
NEMUS Bioscience is developing cannabinoid-based therapies for diseases including glaucoma, chemotherapy-induced nausea and vomiting (CINV), and chemotherapy-induced peripheral neuropathy (CIPN). Their lead product candidates include NB1111, a THC prodrug for glaucoma, and NB1222, a THC prodrug suppository for CINV. NEMUS has exclusive rights to cannabinoid compounds and formulations from the University of Mississippi, the only federally-approved source of cannabis compounds in the US. They are developing these prodrugs to improve bioavailability and provide more predictable delivery compared to existing oral cannabinoid therapies.
Nemus Bioscience Inc. Investor Presentation (062915)NemusBioscience
NEMUS Bioscience is developing cannabinoid-based pharmaceuticals to treat unmet medical needs. It has licensed intellectual property from the University of Mississippi related to novel delivery methods and compositions of cannabinoids. Its lead product NB1111 is a proprietary formulation of a THC prodrug being developed as a topical treatment for glaucoma, with the potential to be the first medication to target the optic nerve through multiple mechanisms in addition to lowering intraocular pressure. NEMUS is seeking funding to complete IND-enabling studies and a Phase 1b/2a clinical trial for NB1111 in glaucoma patients.
NEMUS Bioscience is a publicly traded biotech company focused on developing cannabinoid-based therapies. The document discusses NEMUS' drug development pipeline including NB1222 for chemotherapy-induced nausea and vomiting (CINV), NB1111 for glaucoma, and research on CBD derivatives for chemotherapy-induced peripheral neuropathy (CIPN) and methicillin-resistant Staphylococcus aureus (MRSA). The document provides market data and potential advantages of NEMUS' prodrug formulations which are designed to improve cannabinoid delivery and avoid first-pass liver metabolism.
NEMUS Bioscience is developing cannabinoid-based therapies using compounds licensed from the University of Mississippi, the only federally-approved source of cannabis in the US. Their lead compound NB1111 is a THC prodrug for glaucoma entering preclinical studies. In addition to ophthalmic targets, NEMUS' pipeline includes programs for MS, anxiety, epilepsy, and MRSA, with various delivery methods including topical ocular, buccal patch, and suppository. The company partners with thought leaders in ophthalmology and cannabinoid science to advance its portfolio of near-term and longer-term projects targeting unmet medical needs.
This document is an investor presentation for NEMUS Bioscience, an OTCQB-listed biotech company developing cannabinoid-based therapies. Some key points:
- NEMUS has a proprietary pipeline led by NB1111, a THC prodrug for glaucoma, and novel CBD derivatives for retinal diseases and chemotherapy side effects.
- Recent milestones include completing a $5M financing, adding experts to their scientific advisory board, partnering with Athyrium to advance programs, and validating NB1111 data showing a 45% reduction in eye pressure.
- NEMUS' cannabinoid prodrug programs have a competitive advantage over orally administered cannabinoids, which
This document provides an overview of NEMUS Bioscience, a biotech company focused on developing cannabinoid-based therapies. Some key points:
- NEMUS is developing therapies using cannabinoids for diseases like glaucoma, cancer, and antibiotic-resistant infections, leveraging 47 years of research from a partner university.
- Their pipeline includes a THC prodrug (NB1111) for glaucoma entering validation studies, and CBD derivatives for chemotherapy-induced nausea and neuropathy.
- Recent milestones include completing a $5M financing, adding experts to their scientific board, initiating programs for glaucoma and chemotherapy side effects, and signing a manufacturing agreement for lead programs.
Nemus Bioscience had a productive year, advancing multiple drug candidates in oncology supportive care, ophthalmology, and anti-infectives. Key achievements included licensing CBD derivatives from the University of Mississippi, completing preclinical studies, and establishing partnerships for drug development and manufacturing. Looking forward, Nemus aims to maintain financing, advance formulations, form strategic partnerships, qualify for grants, and increase awareness to support its pipeline of cannabinoid-based therapies. The main challenges will be securing adequate capital and establishing partnerships to fund development in a non-dilutive manner.
Symposium Investor Roadshow November 2015 - MGC PharmaceuticalsSymposium
MGC Pharmaceuticals (MGC) is a medical and cosmetic cannabis company with licenses to grow, extract and sell Cannabis Sativa in Slovenia within the EU. MGC holds unique genetics with very low THC levels and high CBD content, allowing it to produce higher amounts of CBD. MGC is currently developing its own line of cosmetic and over-the-counter medical products and has partnerships to sell CBD extracts. The company sees opportunities in the Australian market following regulatory changes.
The document summarizes IntelGenx's Q4 and full year 2015 financial results. Key points include:
- Record revenue in Q4 2015 and full year 2015, demonstrating strong execution of their strategy.
- Continued growth of Forfivo XL sales, with Q4 2015 net sales increasing 24% over Q3 2015.
- Completion of construction of a new manufacturing facility that will lower costs and improve quality control.
- Strengthened management team to accelerate business development and product pipeline expansion.
- Outlook for continued revenue growth from commercialization efforts and new product opportunities utilizing their oral thin film technology platform.
The document is an investor presentation by IntelGenx, an innovative drug delivery solutions company. It summarizes the company's business strategy, product pipeline, and financial performance. Key points include IntelGenx's focus on repurposing drugs using its oral thin film technology, its partnerships with companies like RedHill and Chemo, its pipeline of products including treatments for migraines and erectile dysfunction, and the construction of its new manufacturing facility. The presentation highlights IntelGenx's potential for growth in the oral thin films market.
NE3107 is a small molecule in Phase 3 clinical trials for Alzheimer's disease and Parkinson's disease. It works by inhibiting neuroinflammation and insulin resistance, two key drivers of cognitive decline. A Phase 3 trial for Alzheimer's is underway testing NE3107's ability to slow cognitive decline compared to placebo. Preclinical studies show NE3107 reduces inflammation, enhances insulin sensitivity, and has neuroprotective effects, supporting its potential in neurodegenerative diseases. A Phase 2 trial will assess NE3107's activity and safety when combined with L-dopa for Parkinson's disease.
One in 8 U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. Following breast cancer surgery in the adjuvant setting, a HER2/neu 3+ patient typically receives Herceptin® in the first year, with the hope that their breast cancer will not recur, and with the odds of recurrence slowly decreasing over the first 5 years after surgery. Herceptin® has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting. In the neoadjuvant setting, a patient receives treatment before surgery and based on the results of a biopsy at surgery, will receive the same or more potent treatment after surgery. Kadcyla® has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting. Accordingly, we believe that GP2 may be used to address the 50% of recurring patients who do not respond to either Herceptin® or Kadcyla®.
- The document is an investor presentation for IntelGenx Corp from April 2018.
- It provides an overview of IntelGenx, including its business strategies, product pipeline, clinical trial results, manufacturing facilities, and leadership team.
- The presentation highlights IntelGenx's drug delivery technology platforms, focus on developing generic and repurposed products, and partnerships with pharmaceutical companies.
One in 8 U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. Following breast cancer surgery in the adjuvant setting, a HER2/neu 3+ patient typically receives Herceptin® in the first year, with the hope that their breast cancer will not recur, and with the odds of recurrence slowly decreasing over the first 5 years after surgery. Herceptin® has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting. In the neoadjuvant setting, a patient receives treatment before surgery and based on the results of a biopsy at surgery, will receive the same or more potent treatment after surgery. Kadcyla® has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting. Accordingly, we believe that GP2 may be used to address the 50% of recurring patients who do not respond to either Herceptin® or Kadcyla®.
SciSparc is a specialty pharmaceutical company developing unique cannabinoid technologies for treatment of central nervous system disorders. The proprietary compounds capitalize on the biochemistry of receptors that specialize in modulating the central nervous system (CNS) to create therapeutics that mitigate the adverse symptoms associated with CNS disorders.
Aptorum Group Limited (NASDAQ: APM) is a pharmaceutical company dedicated to
developing and commercializing novel therapeutics to tackle unmet medical needs.
Aptorum's current drug pipeline includes indications in orphan diseases, infectious
diseases, and metabolic diseases. In 2021, the company plans to bring two candidates to
clinical trials. Aptorum’s Smart-ACT™ platform is designed to bring an average of three
drug candidates for orphan diseases to clinical trials every 12-18 months. The company is
now preparing to launch a dietary supplement for women undergoing menopause and
experiencing related symptoms, including osteoporosis. Targeting a global woman’s health
supplement market that is expected to reach $17 billion in 2025, Aptorum is expected to
generate near-term revenue with significant long-term growth potential.
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of drug candidates intended to transform existing treatment and prevention paradigms. Its lead Phase 3 antifungal candidate, rezafungin, will report Phase 3 data at the end of 2021. The potential peak sales opportunity for rezafungin in the US is ~$750M. In addition, the Company is developing Drug-Fc Conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform.
Virios Therapeutics is a clinical-stage biotechnology company focused on advancing novel, dual mechanism antiviral therapies to treat conditions associated with virally triggered or maintained immune responses, such as Fibromyalgia (“FM”). Immune responses related to the activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) have been postulated as a potential root cause triggering and/or sustaining chronic illnesses such as FM, irritable bowel disease (“IBS”), and chronic fatigue syndrome, all of which can be characterized by waxing and waning symptom flare-ups with no obvious etiology. Virios’ lead development candidate (“IMC-1”) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress HSV-1 replication, with the end goal of reducing virally promoted disease symptoms.
HR Compliance & Insurance Benefit Perspectives: What Employers Should Be Awar...Rea & Associates
Guidelines for employees are constantly changing but it’s important that businesses stay on top of mandates and regulations. What risks should organizations be informed about? Is your organization able to have varied insurance premiums for vaccinated vs. non-vaccinated employees?
Join Rea & Associates and Huntington Insurance for a deep dive into best practices for exposures, insurance perspectives, and vaccine mandates and regulations.
This document provides an overview of NEMUS Bioscience, a publicly traded life sciences company focused on developing cannabinoid-based therapies. Some key points:
- NEMUS has exclusive partnerships with the University of Mississippi, the only entity licensed to study cannabinoids, giving it access to 48 years of research.
- It has a pipeline of drug candidates targeting large markets like glaucoma, chemotherapy side effects, and pain, in preclinical and research stages.
- Target indications include ocular diseases, anti-infectives for bacteria/viruses, and pain syndromes.
- Recent milestones include in-licensing a CBD derivative from UM to research chemotherapy induced
Nemus Bioscience is developing cannabinoid-based therapies focused on treating glaucoma and other conditions. Their lead product NB1111 is a THC prodrug being developed for glaucoma, with plans to initiate a Phase 1b/2a clinical trial in Australia. If successful, NB1111 has the potential to provide IOP reduction and neuroprotection - advantages over current glaucoma drugs. Nemus has partnerships with Emerald Health Sciences and the University of Mississippi providing intellectual property rights and development expertise in cannabinoid research.
This document provides an overview of NEMUS Bioscience, a biotech company focused on developing cannabinoid-based therapies. It discusses NEMUS' partnership with the University of Mississippi, its product pipeline including treatments for glaucoma, chemotherapy side effects, and antibiotic-resistant infections, and provides highlights of recent milestones such as positive studies of a drug for glaucoma and the identification of a molecule for chemotherapy-induced neuropathy. The document also gives financial information about NEMUS and states that it is advancing therapies in large potential markets through proprietary cannabinoid molecules.
NEMUS Bioscience is developing cannabinoid-based therapies for diseases including glaucoma, chemotherapy-induced nausea and vomiting (CINV), and chemotherapy-induced peripheral neuropathy (CIPN). Their lead product candidates include NB1111, a THC prodrug for glaucoma, and NB1222, a THC prodrug suppository for CINV. NEMUS has exclusive rights to cannabinoid compounds and formulations from the University of Mississippi, the only federally-approved source of cannabis compounds in the US. They are developing these prodrugs to improve bioavailability and provide more predictable delivery compared to existing oral cannabinoid therapies.
Nemus Bioscience Inc. Investor Presentation (062915)NemusBioscience
NEMUS Bioscience is developing cannabinoid-based pharmaceuticals to treat unmet medical needs. It has licensed intellectual property from the University of Mississippi related to novel delivery methods and compositions of cannabinoids. Its lead product NB1111 is a proprietary formulation of a THC prodrug being developed as a topical treatment for glaucoma, with the potential to be the first medication to target the optic nerve through multiple mechanisms in addition to lowering intraocular pressure. NEMUS is seeking funding to complete IND-enabling studies and a Phase 1b/2a clinical trial for NB1111 in glaucoma patients.
NEMUS Bioscience is a publicly traded biotech company focused on developing cannabinoid-based therapies. The document discusses NEMUS' drug development pipeline including NB1222 for chemotherapy-induced nausea and vomiting (CINV), NB1111 for glaucoma, and research on CBD derivatives for chemotherapy-induced peripheral neuropathy (CIPN) and methicillin-resistant Staphylococcus aureus (MRSA). The document provides market data and potential advantages of NEMUS' prodrug formulations which are designed to improve cannabinoid delivery and avoid first-pass liver metabolism.
NEMUS Bioscience is developing cannabinoid-based therapies using compounds licensed from the University of Mississippi, the only federally-approved source of cannabis in the US. Their lead compound NB1111 is a THC prodrug for glaucoma entering preclinical studies. In addition to ophthalmic targets, NEMUS' pipeline includes programs for MS, anxiety, epilepsy, and MRSA, with various delivery methods including topical ocular, buccal patch, and suppository. The company partners with thought leaders in ophthalmology and cannabinoid science to advance its portfolio of near-term and longer-term projects targeting unmet medical needs.
This document is an investor presentation for NEMUS Bioscience, an OTCQB-listed biotech company developing cannabinoid-based therapies. Some key points:
- NEMUS has a proprietary pipeline led by NB1111, a THC prodrug for glaucoma, and novel CBD derivatives for retinal diseases and chemotherapy side effects.
- Recent milestones include completing a $5M financing, adding experts to their scientific advisory board, partnering with Athyrium to advance programs, and validating NB1111 data showing a 45% reduction in eye pressure.
- NEMUS' cannabinoid prodrug programs have a competitive advantage over orally administered cannabinoids, which
This document provides an overview of NEMUS Bioscience, a biotech company focused on developing cannabinoid-based therapies. Some key points:
- NEMUS is developing therapies using cannabinoids for diseases like glaucoma, cancer, and antibiotic-resistant infections, leveraging 47 years of research from a partner university.
- Their pipeline includes a THC prodrug (NB1111) for glaucoma entering validation studies, and CBD derivatives for chemotherapy-induced nausea and neuropathy.
- Recent milestones include completing a $5M financing, adding experts to their scientific board, initiating programs for glaucoma and chemotherapy side effects, and signing a manufacturing agreement for lead programs.
Nemus Bioscience had a productive year, advancing multiple drug candidates in oncology supportive care, ophthalmology, and anti-infectives. Key achievements included licensing CBD derivatives from the University of Mississippi, completing preclinical studies, and establishing partnerships for drug development and manufacturing. Looking forward, Nemus aims to maintain financing, advance formulations, form strategic partnerships, qualify for grants, and increase awareness to support its pipeline of cannabinoid-based therapies. The main challenges will be securing adequate capital and establishing partnerships to fund development in a non-dilutive manner.
Symposium Investor Roadshow November 2015 - MGC PharmaceuticalsSymposium
MGC Pharmaceuticals (MGC) is a medical and cosmetic cannabis company with licenses to grow, extract and sell Cannabis Sativa in Slovenia within the EU. MGC holds unique genetics with very low THC levels and high CBD content, allowing it to produce higher amounts of CBD. MGC is currently developing its own line of cosmetic and over-the-counter medical products and has partnerships to sell CBD extracts. The company sees opportunities in the Australian market following regulatory changes.
The document summarizes IntelGenx's Q4 and full year 2015 financial results. Key points include:
- Record revenue in Q4 2015 and full year 2015, demonstrating strong execution of their strategy.
- Continued growth of Forfivo XL sales, with Q4 2015 net sales increasing 24% over Q3 2015.
- Completion of construction of a new manufacturing facility that will lower costs and improve quality control.
- Strengthened management team to accelerate business development and product pipeline expansion.
- Outlook for continued revenue growth from commercialization efforts and new product opportunities utilizing their oral thin film technology platform.
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH. Can-Fite’s drugs have an excellent safety profile with experience in over 1,000 patients. Can-Fite’s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date. Visit CANFinfo.com to learn more
The presentation summarizes IntelGenx, a drug delivery company focused on oral thin film technologies. It discusses IntelGenx's strategy to develop and commercialize improved drug delivery products using its oral thin film platform. Key points include successful commercial partnerships, a robust product pipeline including generic and branded products, positive clinical trial results, and a new manufacturing facility positioned for growth. Financial results show increasing revenue and adjusted EBITDA. The presentation positions IntelGenx as a leader in oral thin films with innovative technology and a clear strategy for growth.
Slides presented by me at the Korean-American Professional Association in Life Sciences (KAPAL) 5th Annual Meeting in Rockville, MD. Slides discuss the recent reorganization of the Center for Drug Evaluation and Research at the FDA
This document provides an overview of pharmacovigilance and the Pharmacovigilance Program of India (PvPI). It defines pharmacovigilance as the science of detecting, assessing, understanding, and preventing adverse effects of medicines. The document outlines the historical events that led to the development of pharmacovigilance, including the sulfanilamide and thalidomide disasters. It describes the vision, mission, aims, and objectives of PvPI in India to improve patient safety related to medicine use. Key aspects of PvPI covered include adverse drug reaction reporting processes and the expansion of PvPI to include additional medical areas over time.
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH. Can-Fite’s drugs have an excellent safety profile with experience in over 1,000 patients. Can-Fite’s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date. Visit CANFinfo.com to learn more.
RespireRx Corporate Slide Deck and Non Confidential Shortened VersionRespireRX
RespireRX Pharmaceuticals Inc. is a publicly-traded company listed on the OTCQB under the ticker symbol RSPI. This is not investment advice. Please view the disclaimer found on this website. http://www.respirerx.com
Discovery of Drug and Introduction to Clinical Trial_Katalyst HLSKatalyst HLS
Introduction to Discovery of Drug and Introduction to Clinical Trials in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical-stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH. Can-Fite’s drugs have an excellent safety profile with experience in over 1,000 patients. Can-Fite’s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date.
UnityNet World Environment Day Abraham Project 2024 Press ReleaseLHelferty
June 12, 2024 UnityNet International (#UNI) World Environment Day Abraham Project 2024 Press Release from Markham / Mississauga, Ontario in the, Greater Tkaronto Bioregion, Canada in the North American Great Lakes Watersheds of North America (Turtle Island).
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
The E-Way Bill revolutionizes logistics by digitizing the documentation of goods transport, ensuring transparency, tax compliance, and streamlined processes. This mandatory, electronic system reduces delays, enhances accountability, and combats tax evasion, benefiting businesses and authorities alike. Embrace the E-Way Bill for efficient, reliable transportation operations.
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4study presented by a Big 4
2. 2
Legal Disclaimer
This presentation contains “forward-looking statements”, including statements regarding Nemus Bioscience, Inc.
and its subsidiaries, within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform
Act of 1995. All of the statements in this presentation, whether written or oral, that refer to expected or
anticipated future actions and results of NEMUS are forward-looking statements. In addition, any statements that
refer to expectations, projections, or other characterizations of future events or circumstances are forward-
looking statements. These forward-looking statements reflect our current projections and expectations about
future events as of the date of this presentation. NEMUS cannot give any assurance that such forward-looking
statements will prove to be correct. The reader is cautioned not to place undue reliance on these forward-looking
statements.
The information provided in this presentation does not identify or include any risk or exposures, of NEMUS that
would materially adversely affect the performance or risk of the company. For a description of the risks and
uncertainties related to the business of NEMUS, see our Annual Report on Form 10-K filed with the Securities and
Exchange Commission and our subsequent periodic reports filed with the Securities and Exchange Commission.
All information contained in this presentation is provided as of the date of the presentation and is subject to
change without notice. Neither NEMUS, nor any other person undertakes any obligation to update or revise
publicly any of the forward-looking statements set out herein, whether as a result of new information, future
events or otherwise, except as required by law. This presentation shall not constitute an offer to sell or the
solicitation of an offer to sell or the solicitation of an offer to buy any securities of Nemus, nor shall there be any
sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such jurisdiction. This is presented as a source of information and
not an investment recommendation.
3. 3
Nemus and Emerald Health
• Emerald Health Sciences is an operating company focused on the medicinal potential
of cannabis and cannabinoids. Its mission is to identify and invest in operating
subsidiaries that offer it unique opportunities and provide appropriate resources to
advance the development of its subsidiaries and their technologies.
• Pursuant to the closing of the initial private placement in January, 2018, Emerald
holds a majority of Nemus’ common shares on a fully converted basis.
• Dr. Brian Murphy is joined by Punit Dhillon and Jim Heppell as directors of the
company. Mr. Dhillon and Mr. Heppell are also directors at Emerald.
Nemus Secures Emerald Health Sciences as Strategic Majority
Investor to help Advance Clinical Development of Novel
Cannabinoid-based Therapeutics
4. 4
NEMUS Value Proposition:
Disrupting the cannabinoid therapeutic space
Developing
Biosynthetic
Cannabinoids
Sole Development &
Commercialization
Partner with UM
Targeting Unmet
Needs in Multi-
Billion Dollar Global
Markets
Proprietary Pipeline
with Global Patent
Footprint
• NEMUS is the sole development and commercialization partner of the University
of Mississippi, drawing on 50 years of intellectual capital in cannabinoid chemistry
and physiology from the only entity with a Federal license to directly study
cannabinoids
• The proprietary prodrug of THC has a global patent footprint including the world’s
largest pharma markets of USA, Japan and the EU
• Developing cannabinoid molecules for the treatment and/or management of
acute and chronic diseases, including a multi-cannabinoid platform for diseases
of the eye, global pain markets, and anti-infectives to combat threats to the
public health
• Currently, the only cannabinoid company with potential cost-effective and enhanced
life-cycle scale-up production related to biosynthetic manufacturing of cannabinoids
• The only cannabinoid company with re-engineered prodrugs and analogues of
cannabinoids designed for multiple routes of administration
5. 5
Exclusive strategic relationship with the University of Mississippi
provides access to a diverse cannabinoid patent estate
The University of Mississippi (UM) is the only entity in the US
authorized by NIDA and the DEA to cultivate cannabis on behalf of
the federal government for 50 years
NEMUS has exclusive, perpetual, worldwide exclusivity for all
compounds and targets we are working on with UM for key fields of
delivery
Patents have been issued for the proprietary prodrug of THC in the
USA (2014), Japan (2015), Australia (2016); EU (2017); UK (2017)
Canada (2017), and Hong Kong (2017)
Nemus and the University are currently engaged in the development
of third-generation hybrid synthetic cannabinoid molecules with the
goal of becoming the leading developer of second- and third-
generation compounds in the field of cannabinoid-related medicines
6. 6
Innovative Cannabinoid Formulations
Designed for Improved Drug Delivery
All NEMUS licensed delivery options optimize our prodrug cannabinoid
technology by enhancing bioavailability by avoiding first-pass liver
metabolism and offering more predictable pharmacokinetics
Glaucoma, Conjunctival
& Retinal Diseases
Ocular Delivery
CINV & CIPN
(suppository and buccal patch)
Transmucosal
Delivery
CIPN & Anti-Infectives
(nasal/transdermal/transmembraneous)
Transmembrane
Delivery
7. 7
Nemus Cannabinoid Development Portfolio
Drug Candidate Target Indications Projected
Global
Market Size
Developmental
stage
NB1111 (Prodrug THC) Glaucoma $3+ B 1 Pre-Clinical
NB1222 (Prodrug THC) Chemotherapy-Induced
Nausea and Vomiting (CINV)
$2 B 2 Pre-Clinical
NB2111 (Analogue CBD) Chemotherapy-Induced
Peripheral Neuropathy (CIPN);
pain syndromes
>$35 B 3 Research
NB2222 (Analogue CBD) Ocular Targets: uveitis, dry eye
syndrome, macular
degeneration, diabetic
retinopathy
> $22 B Research
Cannabinoid Platform
NB3111
Methicillin-resistant Staph
aureus (MRSA); gram-positive
bacteria; viral species
>$6 B 4 Research
1. GlobalData; 2015
2. Transparency Market Research, 2014
3. Transparency Market Research, 2016
4. Pew Trust MRSA Survey, 2012
8. 8
Nemus Ophthalmology Pipeline
NB1111 (THC-Valine-Hemi-Succinate: THCVHS)
is globally patented for composition of
matter and methods of use and is being
developed for the treatment and
management of glaucoma
Prodrug of THC
(NB1111)
NB2222, a proprietary analog of cannabidiol
(CBD), is undergoing testing as a therapeutic
candidate for dry eye syndrome (DES)
Analog of CBD
(NB2222)
10. 10
The Glaucoma Market
Large Market
High Unmet Medical
Need
Well Defined
Regulatory Path
Cannabinoids
Demonstrate Efficacy
& Neuroprotection
Early Development
M&A
• $3+ billion globally and growing with aging populations
• $2.6 billion US market (35 MM Rx)*
• Glaucoma as a “Non-responder” market presents greater opportunities;
>50% of patients on 2 or more Rx
• Regulatory strategy:
• Potential for “urgent medical need” and “breakthrough therapy” FDA
designations
• Cannabinoids have exhibited neuroprotective qualities in vitro and in vivo
(multiple animal species) related to preservation of the optic nerve
• Historically, licensing and acquisitions in the glaucoma market occur
predominantly earlier in development (pre-clinical & phase 1)
• A leading cause of irreversible blindness in the US due to death of retinal
ganglion cells (RGS)
* IMS; 2016
11. 11
Cannabinoid receptors in the eye
• Modulation of cannabinoid receptor tone
already exists by virtue of the endocannabinoid
system located in the eye and other organs
• CB1 receptors display a higher density in the
anterior compartment than the posterior (1)
• CB1 receptors have been localized to ciliary
epithelium, ciliary muscle, trabecular
meshwork, canal of Schlemm, iris; organs that
help regulate intra-ocular pressure (IOP) (2)
• CB1 receptors have also been localized in lower
density in the posterior compartment in the
choroid and retina (3)
• CB2 receptors are more prevalent in the
posterior compartment of the eye (1)
1. Porcella A et al; Eur J Neuroscience, 2000; 12:1123-1127
2. Chien FY, et al. Arch Ophthal, 2003; 121:87-90
3. Wei Y, et al. Molecular Vision, 2009; 15: 1243-1251
12. 12
THCVHS vs THC: CB receptor dynamics*
*Goutham R, et al. IVOS, 2017; 58(4): 2167-2179
• Experiments have shown that THCVHS does not substantively bind CB receptors
• The physiological effect comes from THC derived from the prodrug
13. 13
NB1111 (THCVHS) vs pilocarpine and timolol achieves
47% reduction in IOP*
*Goutham R, et al. IVOS, 2017; 58(4): 2167-2179
14. 14
• THCVHS in Tocrisolve
exhibits IOP maximum
decline of 47%
• THCVHS in SLN exhibits
IOP maximum decline of
35%
• THC in SLN exhibited
roughly 8-10% decline in
IOP
• Encapsulating THCVHS
in an SLN enhanced the
half-life by almost
doubling the time of
physiologic effect
NB1111 vs THC IOP reduction:
Prodrug achieves significant decline in IOP
SOLID LIPID NANOPARTICLE (SLN) TECHNOLOGY ENHANCES HALF-LIFE
15. 15
• Drug localizes to ocular organs
responsible for IOP regulation
• No THC detected in the plasma
of the study animals even after 5
days of dosing
• THC alone,
administered in
an SLN showed
no appreciable
concentration in
ocular tissues
regulating IOP,
compared to
NB1111, the
prodrug of THC
Enhanced tissue penetration of NB1111 associated
with superior efficacy in rabbit glaucoma model
16. 16
Cannabinoids Shown to Be Neuroprotective in Multiple
Animal Models Assessing Integrity of the Optic Nerve
• Cannabinoid agonists have shown both
a clear hypotensive and neuroprotective
effect on retinal ganglion cells (RGCs)
• CB1 receptors, to a greater extent than
CB2 receptors, have been implicated in
mediating cannabinoid-induced
neuroprotection
• Experimentally, in multiple animal
species, synthetic and endogenous
cannabinoids have displayed a
protective effect on neurons
• Possible mechanism related to
disrupting the glutamate-NMDA
apoptosis cycle in RGCs
17. 17
NB1111 (Glaucoma/Ophthalmology)
Multi-Chamber
Ocular Penetration
Lowers IOP
Posterior Chamber
Entry &
Neuroprotection
Potential Reduction
of Adverse Events
Primary &
Adjunctive
Therapy Markets
• Penetrates multiple chambers of the eye in test animals
• The proprietary formulation allows THC to be absorbed across membranes that are
normally barriers to absorption
• Potentially first medication to exert direct neuroprotection of the optic nerve
(retinal ganglion cells; RGCs) by inhibiting apoptosis pathway
• No detectable THC or 11-OH-THC found in systemic circulation after multiple doses
(ng sensitivity of detection)
• Cannabinoid-class molecules administered directly into the eye could offer a
treatment option to lower risk of serious or systemic adverse events
• By virtue of safety/efficacy/neuroprotection profile of cannabinoid-class
molecules, NB1111 could be a potential primary or adjunctive therapy in
managing glaucoma
• Produces a 47% reduction in Intra-Ocular Pressure (IOP) in glaucoma animal model
in Tocrisolve suspension; roughly 35% in half-life extending solid lipid nanoparticles
19. 19
The Dry Eye Market
1. Future Market Insights, 2017
Large & Growing
Global Market
High Unmet
Medical Need
Cannabinoids May
Address
Underlying Cause
& Symptoms of
DES
• $3.56 billion Global Market1 in 2017 and growing
• $6.6 billion Global Market expected by 20271
• Significant non-responder market; more than 50% of patients do not respond to
currently approved medications
• Efficacy still a major unmet need in the DES space and patients continue to
seek symptom relief even while on currently approved medications
• New drugs in development have failed to address underlying cause
• Patient satisfaction often hinges on the resolution of accompanying
neuropathic ocular pain in DES and drives perception of treatment success
• Clinical studies have provided evidence that cannabinoids are effective in
suppressing neuropathic pain states in humans
• CBD, by virtue of its anti-inflammatory properties, may be a treatment
option for the pain and discomfort associated with DES in the anterior
compartment, by modulating the formation of tumor necrosis factor (TNF)
and scavenging reactive oxygen species (ROS)
20. 20
NB2222: Assessing ocular permeation
STUDY PURPOSE
• Cannabidiol (CBD) is one of the active components of the plant Cannabis sativa and
has been studied in the management of neurological diseases, sleep disorders, and
the management of pain.
• CBD, by virtue of its anti-inflammatory properties, might also be a treatment option
for the pain and discomfort associated with dry eye syndrome in the anterior
compartment as well as diabetic retinopathy induced pain and inflammation in the
posterior compartment, by modulating the formation of tumor necrosis factor (TNF)
and scavenging reactive oxygen species (ROS).
• CBD is a lipophilic molecule (log P 5.9) making its topical delivery to target tissues of
the eye extremely challenging.
• This work aims at improving ocular penetration of CBD by means of analogue
derivatization.
Pranjal, et al, AAPS, 2017, poster M5100
21. 21
Tissue distribution of CBD derivatives: Bio-engineered
NB2222 outperforms other forms of cannabidiol
*AH= aqueous humor; IC= iris/ciliary bodies; RC= retina choroid; VH= vitreous humor
22. 22
Bio-engineering
Improved Ocular
Permeation
Potential Dual
MOA:
Reduce Ocular
Neuropathic Pain &
Inflammation
• NB2222 (CBDVHS) demonstrated best ocular bioavailability1
• NB2222 demonstrated tissue penetration in both anterior and posterior
compartment1
• NB2222 displayed the most potent CBD activity1
• NB2222 showed enhanced molecular stability vs. other derivatives1
• NB2222 emerged as the most optimal candidate to advance into in vivo studies1
• Clinical studies provide substantial evidence that cannabinoids show efficacy in
suppressing diverse neuropathic pain states in humans
• Potentially first medication to exert dual mechanisms of action (MOA):
direct analgesic effect on neuropathic pain while simultaneously reducing
inflammation in DES
NB2222 (Dry Eye/Ophthalmology)
1. Pranjal, et al, AAPS, 2017, poster M5100
23. 23
Analogue of CBD: NB2111
For the treatment of
Chemotherapy-induced
peripheral neuropathy (CIPN)
A dose-dependent complication associated with many types of
chemotherapeutic agents
24. 24
The CIPN Market
Large Global
Market
High Unmet
Medical Need
Cannabinoids
Demonstrate
Efficacy
Potential
Alternative For
Opioid Abuse
Epidemic
• The overall global pain market is projected to be $35 billion by 20171
• CIPN market in the United States exceeds $500 MM2
• The parallel opioid-induced constipation market is estimated to be $600 MM
globally3
• In addition to severe, sometimes unremitting pain, it often leads to premature
discontinuation of chemotherapy compromising cancer cure rates.
• Current agents possess side effects such as nausea, vomiting, constipation and
respiratory depression, in addition to complications of tolerance and abuse
associated with opioids
1 GBI Research: Global Pain Markets, 2015
2 LifeSci Advisors, 2013
3 GlobalData, 2015
• Clinical studies provide evidence that cannabinoids show efficacy in
suppressing neuropathic pain states in humans
• Cannabinoids suppress hyperalgesia and allodynia induced by neuropathic pain
states through CB1 and CB2 specific mechanisms
• Opioid abuse now at epidemic proportions globally
• Government officials and patient advocacy groups are calling for the
exploration of medical cannabinoids as alternatives to opioid-based analgesics
25. 25
Figure 2: Mean (+ SEM) paw withdrawal in grams of force. Dashed lines depict baseline responses pre- and post-
cisplatin administration protocol prior to drug efficacy screening. Vertical bars represent responses on drug efficacy
screening day for drug treatment conditions. * denotes significant attenuation of tactile allodynia compared to the
vehicle group (p < 0.05). Sample sizes were n = 9-11
NB2111 (CBDVHS) versus Morphine in murine allodynia
model exhibits dose-response pain mitigation
NB2111 exhibits comparable pain control
compared to morphine in animal CIPN study
26. 26
NB2111 demonstrated anti-addiction qualities
• 3 mg/kg of OXY had
significant impact on place
preference consistent with
drugs of abuse
• When OXY is formulated
with CBDVHS, decreasing
OXY reward peaks at
8mg/kg of CBDVHS
• None of the CBDVHS
doses when given alone
exhibited abuse liability
nor adverse events in the
animals
The effects of CBD-val-HS on oxycodone (OXY)
place preference scores
27. 27
NB2111 (Pain Management)
Significant Efficacy
(Analgesia)
Attenuates Opioid
Addictive Response
Primary &
Adjunctive Therapy
Markets
• Dual profile of analgesia and abuse attenuation, NB2111 could be a potential
primary or adjunctive therapy in managing CINP as well as other types of
pain syndromes
• NB2111 is a CBD-like molecule tested in a murine model of tactile allodynia
replicating the neuropathy associated with exposure to the chemotherapeutic
agent of cisplatin (used in lung, breast and colon cancers)
• NB2111 resulted in significant analgesia in this model with analgesic coverage
commensurate with that seen using the highest dose of morphine exposure
• Data demonstrate an efficacious dose of NB2111 blocks oxycodone (OXY)
reward when combined with sub-analgesic and analgesic dosages of OXY
• Studies to be planned examining both analgesia potential and anti-abuse
advantage when dosing NB2111
29. 29
The MRSA Market
Significant
Multi-segmented
Market
High Unmet
Medical Need
MRSA Recognized as
International Health
Threat
Regulatory Agency
Incentives
Cannabinoids
Demonstrate Efficacy
Against MRSA
• MRSA spend exceeds $6 billion Globally4
• Prevalence in most countries has exceeded 25% with many exceeding 50%1
• Pipeline of innovative antibiotics with activity against MRSA possess liver and renal
adverse effects
• 2017: WHO lists MRSA as a high priority pathogen for new antibiotic R&D focus
• 2016: U.N. General Assembly drafts political declaration on threat of Antimicrobial Resistance
• Significant morbidity and mortality
• MRSA is responsible for more US deaths annually than any other serious infectious disease2
• CDC: prevalence of MRSA in ICU setting approaching 60% 3
• 11,000 deaths annually; 80,000 invasive infections/yr.4
• Annual costs in the US: $3.2 - $4 billion5
• Select cannabinoids have been known to possess antibacterial properties5
• FDA & EMA establish Qualified Infectious Disease Product (QIDP) designation for threats
like MRSA to incentivize drug development
• QIDP designation can impact expedited review, prioritization of NDA submission, and
additional market exclusivity
1. Grundmann et al., Lancet 368 (2006) 874-885
2. DeLeo, J. et al, J Clin Invest. 2009 Sep 1; 119(9): 2464–2474
3. Jarvis WR et al; Am J Infect Control 2012; 40(3): 194-20
4 Pew Trust MRSA Survey; April 3, 2012
5. J Nat Prod. 2008 Aug;71(8):1427-30. doi: 10.1021/np8002673. Epub 2008 Aug 6.- Antibacterial cannabinoids from Cannabis sativa: a structure-activity study
30. 30
Significant Mortality Associated with MRSA
DeLeo, J. et al, J Clin Invest. 2009 Sep 1; 119(9): 2464–2474
MRSA is responsible for more US deaths annually than any other
serious infectious disease
31. 31
MRSA Has Become a Global Urgent Health Concern
International Health Initiatives to Incentivize Discovery
U.N. Sept 21st, 2016 Draft Political Declaration of the High–level Meeting
Of the General Assembly on Antimicrobial Resistance
32. 32
NB3111 anti-bacterial cannabinoid cocktails
• NEMUS proprietary cannabinoid cocktails exert potent killing power against
multiple species of MRSA in in vitro experimentsSynergistic
Efficacy
Significant Life
Cycle Extension
Opportunities
Multiple MRSA
Market Segments
• Colonization: global mupirocin market $350 million; 50-70% resistance
• Superficial soft tissue infection
• Deep soft tissue infection
• Systemic staph infection
• Gram Positive potential product extensions especially against organisms listed on
bioterrorism listing
33. 33
Nemus Revised Pipeline Timeline Relative to Goals (I)
• Lack of adequate financing in 2017 placed severe constraints on moving development
forward across product silos
• The acquisition of Nemus by Emerald Health permitted a capital infusion to re-energize
development programs
• The multi-billion dollar disease targets identified by Nemus are global and in most
cases, represent urgent medical need
• The overriding goals of Nemus are to advance programs until drug candidates can be:
• Co-developed with a partner
• Out-licensed to a partner
• Sale of the molecule to an acquirer
• Development is now focused on utilizing active pharmaceutical ingredient (API) that is
biosynthetically manufactured to introduce this into the testing and regulatory process;
we anticipate long-term cost-efficiencies associated with this method of manufacturing
35. 35
Management
BRIAN MURPHY, MD, MPH, MBA – Chief Executive Officer; Chief Medical Officer, Director
Dr. Murphy has almost two decades of experience in drug development and evaluation, both from the academic and industry
perspective. He most recently served as the CMO of Eiger Biosciences. Previously, Dr. Murphy was CMO at Valeant
Pharmaceuticals International (VRX) where his responsibilities also included oversight of Global Medical Affairs, Clinical
Development, Biostatistics, and Pharmacovigilance. Dr. Murphy also served as Medical Director, then VP of Marketing and
Commercial Strategy of Hepatology for InterMune, Inc. (ITMN). Prior to InterMune, Dr. Murphy was Medical Director of North
America for Antivirals/Interferons at Hoffmann-LaRoche. Murphy is board-certified in internal medicine and completed his
residency at Tufts-New England Medical Center. He served as Chief Medical Resident in the Boston University Internal Medicine
program. He went on to complete parallel fellowship tracts at Harvard Medical School (HMS) and the Massachusetts General
Hospital in medicine and clinical epidemiology. He also completed a fellowship in Medical Ethics at HMS-Brigham and Women’s
Hospital. Dr. Murphy earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York Medical
College and is a graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA
at the Columbia University Graduate School of Business.
LIZ BERECZ, MA, CPA - Chief Financial Officer
Elizabeth Berecz is a seasoned financial executive with over 20 years of experience holding senior level positions in both private
and public companies. She has proven success in leading strategic planning, financial reporting, and global system
implementations for companies of various sizes. Liz started her career at Price Waterhouse Silicon Valley where she spent five
years auditing several high profile public companies in the technology industry. She then spent 10 years holding key leadership
positions in various publicly held Companies including Quantum Corporation (Corporate Controller), Business Objects (VP
Finance and Administration), and Excite (VP Finance), followed by 10 years of key leadership roles in privately held Companies
including CFO positions with Optical Shop International, StarTrac Inc., Power Balance Technologies, Inc. and most recently
Bentley Mills, Inc. She also serves as an Adjunct Professor of Accounting and Finance at the University of San Francisco.
Elizabeth received her BA in Economics from Stanford University and a MA in Sports Management from University of San
Francisco.
36. 36
Board of Directors and Strategic Advisors
MAHMOUD A. ELSOHLY, PHD
Scientific Advisor
World’s foremost expert on the science
of cannabinoids. 300+ scientific
publications. Research professor at The
University of Mississippi.
Jim Heppell, Esq
Board of Directors
Mr. Heppell is the former founder, CEO
and director of BC Advantage Life
Sciences I fund and is currently a
director at a number of public and
private life science companies. Mr.
Heppell has extensive experience in
corporate finance law.
Punit Dhillon, BA
Board of Directors
Mr. Dhillon is the co-founder and CEO of
OnoSec Medical, Inc. and the former
Vice President of Finance and
Operations at Inovio Pharmaceuticals,
Inc. He has extensive management
experience spanning corporate finance
and M&A to strategy implementation.
Avtar Dhillon, MD
Executive Chairman of Emerald and
Strategic Advisor to Nemus
Dr. Dhillon is currently the Executive
Chairman for Emerald Life Sciences and
the former President and CEO of Inovio
Pharmaceutics Inc. He is a life sciences
entrepreneur with more than 20 years’
experience building public companies.
DONALD I. ABRAMS, M.D.
Scientific Advisor
Chief, Hematology/Oncology at UCSF
Cancer and Integrative Medicine specialist
with research interests in the
development of anti-cancer therapeutics
and palliative care medicines.
37. 37
Contact
600 Anton Blvd., Suite 1100
Costa Mesa, CA 92626
949-396-0330
hello@nemusbio.com
www.nemusbioscience.com
Investor Relations:
Adam Holdsworth
PCG Advisory Group
Tel: 646-862-4607
adamh@pcgadvisory.com
Company:
Brian Murphy, MD, MPH, MBA
CEO - CMO
brian@nemusbio.com